AGENDA :: UNIVERSITY STARTUPS CONFERENCE
March 20 to 21, 2014
Walter E. Washington Convention Center
Washington, DC

NOTE: This Agenda will be updated periodically; panel/showcase dates and time, panels and speakers may change without notice as the conference develops. All listed speakers are confirmed.

THURSDAY, March 20, 2014

TIME:
7:30 am - 8:30 am  Registration and Breakfast
8:30 am - 8:40 am  University Startups Conference
8:40 am - 8:50 am  KEYNOTE:

- Clare Asmail, NIST  
  click to set-up meeting time
- Frank Barros, DHS  
  click to set-up meeting time
- Steve Ferguson, NIH  
  click to set-up meeting time
- Todd Hain, NIH  
  click to set-up meeting time
- Ben Schrag, NSF  
  click to set-up meeting time
- Ali Andalibi, University-Angel Committee  
  click to set-up meeting time
- Paul Corson, Innovation Fund America  
  click to set-up meeting time
- Tony Stanco, NCET2  
  click to set-up meeting time
8:50 am - 9:35 am  PANEL: STATE STARTUP AND SBIR PROGRAMS

- Pravina Raghavan, SBA
  - click to set-up meeting time
- Stephen Auvil, Maryland TEDCO
  - click to set-up meeting time
- COMPANIES SHOWCASED: Cordex Systems, Ionova Technologies, Rehabsys, Weinberg Medical Physics, Infratrac
- Sean Mallon, Center for Innovative Technology
  - click to set-up meeting time
- COMPANIES SHOWCASED: Neoantigenics, ROI², PublicRelay, Wiretough Cylinders
- Lee Herron, Georgia Research Alliance
  - click to set-up meeting time
- COMPANIES SHOWCASED: Soneter, Accutis, Lumense, Viavune
- Nick Pappas, MassVentures
  - click to set-up meeting time
- COMPANIES SHOWCASED: Content Raven, Energid Technologies, mZeal Communications
- Todd Haim, National Cancer Institute, National Institutes of Health
  - click to set-up meeting time
  - COMPANIES SHOWCASED: Cantel, Tensive Controls

9:35 am - 10:20 am  University Startup Portfolio Showcases 2

- Andrew Koopman, New York University
  - click to set-up meeting time
- COMPANIES SHOWCASED: Aria Neurosciences, BeneVir Biopharm, CytoDol Technologies, Inthera Biosciences, Oculogica
Canget Technology Status

- FL118, a small molecule, overcomes multiple drug resistance mechanisms to effectively and safely eliminate human colon tumors in animal models.
- NCI just awarded Canget an SBIR Fast-Track to help bring FL118 to an IND.
- Available data suggest GLP PK and Tox findings will allow for clinical use.
- We expect to file an IND for clinical testing of FL118 within three years.
- Canget has an active back-up program and several promising back-up compounds are in the pipeline, as are other cancer indications.
- Current US Market size for colon cancer is around $2.88B annually.
- Canget has a strong team and scientific advisors, including Dr. Mansukh Wani, the founder of Taxol and Camptothecins, and Dr. Enrico Mihich, the founder of Grace Cancer Drug Center at Roswell Park Cancer Institute and the former AACR President and NCI Board member.
- (For more information, see Canget website: www.canget-biotek.com)